Latest ERYP reports update at 2024-05-14: 2022 ∙ 2021 ∙ 2020

ERYTECH Pharma S.A. ERYP

$ 0.78 1.3%

ERYTECH Pharma S.A. Balance Sheet 2011-2024 | ERYP

Annual Balance Sheet ERYTECH Pharma S.A.

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-28.5 M	-70.4 M	-133 M	-183 M	-34.8 M	-45.1 M	-36.2 M	-14.1 M	3.07 M	-
Long Term Debt	-	-	14.4 M	1.32 M	1.24 M	1.98 M	2.66 M	63 K	436 K	731 K	6.4 M	-
Long Term Debt Current	775 K	1.82 M	1.61 M	1.42 M	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	24.5 M	13.1 M	1.59 M	2.24 M	2.98 M	251 K	525 K	848 K	6.69 M	-
Total Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	53.9 M	33 M	22.2 M	13.8 M	9.33 M	5.87 M	4.78 M	4.36 M	14.2 M	-
Deferred Revenue	-	-	148 K	61 K	16 K	-	-	-	368 K	649 K	943 K	-
Retained Earnings	-	-	-73.3 M	-62.7 M	-38.2 M	-33.5 M	-21.9 M	-15 M	-8.86 M	-8.14 M	-2.17 M	-
Total Assets	45.8 M	66.8 M	80.4 M	119 M	168 M	195 M	45 M	53 M	40.6 M	17.9 M	10.1 M	-
Cash and Cash Equivalents	38.8 M	33.7 M	44.4 M	73.2 M	134 M	186 M	37.6 M	-	-	-	-	-
Book Value	-	66.8 M	26.5 M	85.6 M	146 M	181 M	35.6 M	47.1 M	35.8 M	13.6 M	-4.03 M	-
Total Shareholders Equity	-	-	26.5 M	85.6 M	146 M	181 M	35.6 M	47.1 M	-	-	-	-

All numbers in EUR currency

Quarterly Balance Sheet ERYTECH Pharma S.A.

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	8.16 M	-	8.82 M	-	9.2 M	-	10.5 M	-	11.3 M	-	8.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	23.9 M	-	24 M	-	24.5 M	-	15.4 M	-	13.1 M	-	9.87 M	-	1.59 M	-	-	-	2.24 M	-	-	-	2.98 M	-	-	-	251 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-	-	-	-	-	-	-	-	-	-	-35 M	-	-62.7 M	-	-29.3 M	-	-38.2 M	-	-	-	-33.5 M	-	-	-	-21.9 M	-	-	-	-15 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	-	-	-	-	66.8 M	-	83.8 M	-	80.4 M	-	89.1 M	-	119 M	-	146 M	-	168 M	-	-	-	195 M	-	-	-	45 M	-	-	-	53 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	-	-	-	-	33.7 M	-	46.3 M	-	44.4 M	-	45.4 M	-	73.2 M	-	94.5 M	-	134 M	-	-	-	186 M	-	-	-	37.6 M	-	-	-	45.6 M	-	-	-	37 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-	-	-	-	66.8 M	-	83.8 M	-	80.4 M	-	89.1 M	-	119 M	-	146 M	-	168 M	-	-	-	195 M	-	-	-	45 M	-	-	-	53 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-	-	-	-	22.8 M	-	36.4 M	-	26.5 M	-	51.1 M	-	85.6 M	-	117 M	-	146 M	-	164 M	-	181 M	-	-	-	35.6 M	-	-	-	47.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in EUR currency